Justin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
The makers of the weight loss drug tirzepatide, which is branded commercially as Zepbound, announced Wednesday the results of a Phase 3 study showing that the drug was effective in treating sleep apnea.
Among those in one drug study, it led to an average apnea-hypopnea index reduction of 27.4 events per hour compared to a reduction of 4.8 events per hour for those on a placebo. In a second study, Zepbound led to an average apnea-hypopnea index reduction of 30.4 events per hour compared to a reduction of six events per hour for those on a placebo. Both studies followed patients for a year.
The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. According to the National Council on Aging, obstructive sleep apnea occurs when the upper airway becomes blocked during sleep, interfering with breathing. Older people, men and people who are overweight are more likely to have sleep apnea. Eli Lilly says that Zepbound uses hormone receptors to help people who are considered obese or overweight lose weight and keep it off.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Target's new self-checkout rules might be a welcome changeJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »
Scientist develops tool to photograph solar eclipses with smartphonesJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »
Abortions increase in 2023 despite Roe v. Wade reversalJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »
New intermittent fasting study had 'surprisingly' negative resultsJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »
AstraZeneca capping COPD, asthma medications at $35 a monthJustin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »
Subway switching from Coke to Pepsi in 2025Justin Boggs is a writer for the E.W. Scripps company. Justin covers anything from politics to sports and entertainment.
Read more »